Patients with renal failure in the final stages undergo the treatment by hemodialysis. Hemodialysis is used to reinstate the intracellular and extracellular fluid environment, by propagation of molecules in solution through a semipermeable membrane along an electrochemical concentration gradient. Blood catching in the dialysis machine and the recurrent phlebotomy may lead to losing about 1-3 g of iron per year. Prohepcidin hormone is an acute phase protein (type II) that plays a major role in the systemic iron irregularities as it is a mediator of anemia in inflammation and regulator of iron metabolism. This study aims to evaluate the effect of hemodialysis on iron hemostasis and its relationship with prohepcidin as an inflammatory marker. This study includes forty four adult male patients with endstage renal failure (in pre and post -treated) by means of chronic hemodialysis-HD with mean age (53.27 ± 13.76 years). The following biochemical investigations have been studied: Prohepcidin, Iron, Ferritin, Transferrin, Total Iron-Binding Capacity (TIBC), The Unsaturated Total Iron Binding Capacity (UIBC), and transferrin saturation (TAST).Decrement of Prohepcidin level on hemodialysis patients in post dialysis with non-significantly compared to pre dialysis, while iron and ferritin was increment in post treated than pre-treated with non-significantly. Hemodialysis affects Prohepcidin levels as it was long duration and Glomerular Filtration rate GFR (cock croft equation) and prohepcidin level affect the iron profile related with the iron store depletion.
Introduction:
Hemodialysis is a process including the perfusion of blood and dialysate on a reverse of a semipermeable membrane. Substances are detached from the blood by diffusion and convection. Excess plasma water is removed by Ultrafiltrating a regular occurrence among patients getting long-term hemodialysis [1] .
Acute phase protein, as a type II, is a prohepcidin released as a small peptide mainly from the liver. It acts as a regulator metabolism of iron and an Venous blood samples are collected from each subject in the morning (5-12am), 5 ml of blood is obtained by vein puncture using a 5 ml disposable syringes. About 3.5 ml in tube with clotting jell and 1.5 ml in another tube anticoagulant. It is left for 15 minutes to clot at room temperature, while the tube with anticoagulant is dispensed at once and then separated by centrifugation at (3000 rpm) for (5 min) to collect plasma. Serum is divided into 2 aliquots; 0.5ml in each eppendorff tubes, each one of them is frozen under (-20) C 0 until being used for assays. Serum prohepcidin is measured by using commercially available ELISA kits, Demeditec Diagnostics (Germany), whilst ferritin DRG Diagnostics (Germany) ELISAKit is also used to measure serum ferritin, and Iron Cromazurol (Linear, Spain) by using spectrophotometer, while transferrin, transferrin saturation (TAST), UIBC was calculated by the following equation: [12] Transferrin = 0.7 * TIBC. %TAST=(serum iron conc.)/(TIBC) *100. UIBC = TIBC-Iron concentration.
Statistical Analysis
The 
Results:
Number of patients with the age ≥ 60 years is significantly higher than the other age groups (43.3%). The mean ± SD of hemoglobin is (10.43 ± 0.28 g/dl) and some characteristics of patients are shown on Table (1), (2). 
Correlation
The association between the studied variables is tested by Pearson's correlation coefficient, where the (pvalues <0.05) is considered as statistically significant (Table 3) . Studying the correlation between serum pro-hepcidin and tested of iron, ferritin, transferrin, TIBC. There is no correlations between serum prohepcidin and parameters as shown in Table ( [18] report that liver hepcidin mRNA expression is positively correlated with Hb, suggesting that the effect of anemia on hepcidin production is greater than that of iron load.
Recombinant human Erythropoietin (rHuEPO) administration may have suppressed hepcidin production, based on a report that hepcidin production is reduced by erythropoietin [19] . (Kulaksiz, et al) [20] find that serum pro-hepcidin concentrations in patients with chronic renal disorder treated with rHuEPO are higher than those in healthy volunteers. The possibility is that hepcidin is removed by hemodialysis due to its small molecular weight [21, 22] . Others have reported significantly higher levels in HD patients.(Eleftheriadis, et al) [23] increment prohepcidin level due to inflammation with deepening anemia. Thus therapeutic interventions play a role in the treatment of anemia [24] . In another study (Faruk, et al) [25] is similar to the present study.
Iron decrement is a common complication in patients on hemodialysis and this may be due to blood loss during this procedure. Serum ferritin measurement allows easier quantitation of iron stores in dialysis patients [14] .
Patients who are on hemodialysis have a lower iron level because of the increased blood loss from: the blood left in the dialyzer circuit, the frequent blood sampling, the low-grade gastrointestinal bleeding, multiple vascular access surgeries, etc. This also may be compounded by decreased oral iron absorption because of dietary restrictions, loss of taste for iron-rich foods, and hepcidinin. Another study (Jairam, el al) [26] is similar to present study.
Treating anemia in hemodialysis patients may correct hemoglobin and aggravates iron deficiency due to the increased iron utilization. For good response, iron should be given by i.v. route for patients with real anemia [27] .
The serum Ferritin (SF) reflects storage iron, absolute iron deficiency in healthy and most pathologic conditions, when (SF) is a good indicator of the amount of iron supply. However, erythropoiesis, malnutrition, malignancies, hemolysis and certain inflammatory conditions such as infections, hepatic dysfunction and renal failure may affect SF level. Due to the increase in ferritin activity in acute phase of renal failure, it appears that the SF cut off level for determination of iron deficiency is probably higher in uremic patients. [28] Transferrin levels in chronic kidney disease are one half to one third of normal levels, diminishing the capacity of the iron-transporting system [29] . This situation is then aggravated by the well-known inability to release stored iron from macrophages and hepatocytes in chronic kidney disease. The concentration of serum iron does not fall until the body`s iron stores are exhausted .As the stores are depleted, the concentration of transferrin rises while the concentration of ferritin falls. Caution is required when assessing patients with inflammatory disease as a low serum iron may not represent iron deficiency .These patients often have reduced concentration of transferrin [30] .
In chronic kidney disease patients, serum is a good indicator of nutritional status also it is clinically related with inflammatory, marker, iron reservoir and survival ratio, though It is changes with time can change the risk of death in HD patients. [31] In another study (Neeta, et al) [32] is similar to present study.
(Taes, et al) [33] correspond to the present study that serum prohepcidin levels are higher than the normal values in the patients on HD, but they are not correlated with the serum iron, TIBC, TSAT, ferritin [34] . Pro-hepcidin is a processing intermediate inflammatory physiology, therefore its assessment is less reflective of iron, because it has eight cysteine that form (4 S-S bridges), resulting in a difficulty to enter a specific antibody toward this body. In another study (Taes, et al) [33] find in HD patients there are no significant correlations between pro-hepcidin levels and age, BMI, duration on dialysis, hemoglobin, serum iron, ferritin, TSAT.
Conclusions:
Hemodialysis affects Prohepcidin levels as it have a long duration and GFR (cock croft equation), and Prohepcidin level affect iron profile related with iron store depletion. 
